公开(公告)号：US20210347784A1

公开(公告)日：2021-11-11

申请号：US17368537

申请日：2021-07-06

Applicant: NOVARTIS AG

Inventor： Ha-Soon CHOI ,  Jiqing JIANG ,  James Paul LAJINESS ,  Bao NGUYEN ,  Hank Michael James Petrassi

IPC: C07D493/08 ,  A61K9/00 ,  A61K31/343

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.

公开(公告)号：US20220127247A1

公开(公告)日：2022-04-28

申请号：US17428353

申请日：2020-02-04

Applicant: NOVARTIS AG

Inventor： Mihai AZIMIOARA ,  Bei CHEN ,  Robert EPPLE ,  James Paul LAJINESS ,  Casey Jacob Nelson MATHISON ,  Juliet NABAKKA ,  Victor Ivanovich NIKULIN ,  Sejal PATEL ,  Dean Paul PHILLIPS ,  Paul Vincent RUCKER ,  Andrew VALIERE ,  Baogen WU ,  Shanshan YAN ,  Xuefeng ZHU

IPC: C07D401/12 ,  C07D401/14 ,  A61K45/06 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/506 ,  A61K31/496 ,  C07D405/14

Abstract: The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

公开(公告)号：US20180086716A1

公开(公告)日：2018-03-29

申请号：US15711984

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D231/56 ,  A61K9/16 ,  A61K9/00 ,  C07D403/12 ,  A61K31/416 ,  C07D401/12 ,  A61K31/454 ,  C07D405/12

CPC classification number: C07D231/56 ,  A61K9/0019 ,  A61K9/1647 ,  A61K31/416 ,  A61K31/454 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20230365580A1

公开(公告)日：2023-11-16

申请号：US18354163

申请日：2023-07-18

Applicant: NOVARTIS AG

Inventor： Ha-Soon CHOI ,  Jiqing JIANG ,  James Paul LAJINESS ,  Bao NGUYEN ,  Hank Michael James PETRASSI

IPC: C07D493/08 ,  A61K9/00 ,  A61K31/343

CPC classification number: C07D493/08 ,  A61K9/0053 ,  A61K31/343

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;




or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.

公开(公告)号：US20210079010A1

公开(公告)日：2021-03-18

申请号：US16620407

申请日：2018-06-07

Applicant: NOVARTIS AG

Inventor： Ha-Soon CHOI ,  Jiqing JIANG ,  James Paul LAJINESS ,  Bao NGUYEN ,  Hank Michael James Petrassi

IPC: C07D493/08 ,  A61K31/343 ,  A61K9/00

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating joint damage or injury in a mammal, for inducing hyaline cartilage production or for inducing differentiation of chondrogenic progenitor cells into mature chondrocytes.

公开(公告)号：US20210188842A1

公开(公告)日：2021-06-24

申请号：US16941395

申请日：2020-07-28

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D471/04 ,  A61P21/00 ,  A61K9/00 ,  A61K9/50 ,  A61K31/437 ,  A61K31/496 ,  A61K31/538

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20190300522A1

公开(公告)日：2019-10-03

申请号：US16335496

申请日：2017-09-21

Applicant: NOVARTIS AG

Inventor： Badry BURSULAYA ,  Andreas FISCH ,  James Paul LAJINESS ,  Rainer MACHAUER ,  Swapnil MALEKAR ,  Hank Michael James PETRASSI ,  Farshad RAMAZANI ,  Anne-Catherine REMOND ,  Thomas ULLRICH ,  Peggy USSELMANN ,  Eric VANGREVELINGHE

IPC: C07D471/04 ,  A61K9/00 ,  A61K9/50 ,  A61P21/00 ,  A61K31/437 ,  A61K31/538 ,  A61K31/496

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.